BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$76.45 USD
-0.89 (-1.15%)
Updated May 22, 2024 04:00 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BMRN 76.45 -0.89(-1.15%)
Will BMRN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Other News for BMRN
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
What You Missed On Wall Street This Morning
Robinhood upgraded, Baidu downgraded: Wall Street's top analyst calls
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)